TSX-V:NRX - TSX Venture Exchange - CA67059R1091 - Common Stock - Currency: CAD
TSX-V:NRX (7/23/2025, 7:00:00 PM)
0.73
-0.01 (-1.35%)
The current stock price of NRX.CA is 0.73 CAD. In the past month the price increased by 5.8%. In the past year, price increased by 15.87%.
NurExone Biologic, Inc. is a pharmaceutical company, which engages in the development and commercialization of biological extracellular vesicles-based technology drug platforms. The firm is engaged in developing a platform for biologically guided exosome-based therapies to be delivered, minimally invasive, to patients who have suffered central nervous system injuries. The Company’s first product, ExoPTEN for acute spinal cord injury, uses exosomes loaded with a specific and proprietary sIRNA sequence as the active pharmaceutical ingredient. Its ExoTherapy is a proprietary platform for developing exosome-based therapies. The NurExone platform technology is expected to offer solutions to drug companies interested in minimally invasive targeted drug delivery for other indications.
NUREXONE BIOLOGIC INC
Minus 1 Entry, Ground Floor Of Bldg B
Haifa ALBERTA IL
Employees: 12
Phone: 972524803034
The current stock price of NRX.CA is 0.73 CAD. The price decreased by -1.35% in the last trading session.
The exchange symbol of NUREXONE BIOLOGIC INC is NRX and it is listed on the TSX Venture Exchange exchange.
NRX.CA stock is listed on the TSX Venture Exchange exchange.
9 analysts have analysed NRX.CA and the average price target is 3.12 CAD. This implies a price increase of 326.86% is expected in the next year compared to the current price of 0.73. Check the NUREXONE BIOLOGIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NUREXONE BIOLOGIC INC (NRX.CA) has a market capitalization of 58.41M CAD. This makes NRX.CA a Micro Cap stock.
NUREXONE BIOLOGIC INC (NRX.CA) currently has 12 employees.
NUREXONE BIOLOGIC INC (NRX.CA) has a support level at 0.71 and a resistance level at 0.75. Check the full technical report for a detailed analysis of NRX.CA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NRX.CA does not pay a dividend.
NUREXONE BIOLOGIC INC (NRX.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
ChartMill assigns a technical rating of 8 / 10 to NRX.CA. When comparing the yearly performance of all stocks, NRX.CA turns out to be only a medium performer in the overall market: it outperformed 56.11% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to NRX.CA. While NRX.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months NRX.CA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -4% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -270.98% | ||
ROE | -440.65% | ||
Debt/Equity | 0.02 |
ChartMill assigns a Buy % Consensus number of 84% to NRX.CA. The Buy consensus is the average rating of analysts ratings from 9 analysts.